List of Therapeutic Companies in Missouri - 14

Biologics

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

Certus International is an integrated Contract Research Organization and Imaging Core Lab Service Company offering a full range of clinical trial management, consulting and imaging services. Certus, founded in 1995, is a company whose goal is to be accessible, reliable and transparent for its clients. We do this, in part, by being flexible, maintaining a flat organizational structure, having a real person answer the phone when you call and constantly improving customer service, no matter how good you think it is. We also strive to maintain an excellent working relationship with the FDA. Every clinical trial we partner on is customized per the sponsor's requested needs and our suggestions based on the experience that hundreds of trials and over 28 years have given us.

Engineered Tissue Solutions (ETS) is an emerging wound care company, re-defining wound care with cutting-edge bioactive glass technology that reduces healing time, minimizes treatment costs and improves patient outcomes. Our flagship product, MIRRAGEN® Advanced Wound Matrix, is a next-generation intervention for wound healing. Using synthetic, absorbable bioactive glass fiber technology, MIRRAGEN accelerates healing, decreases wound area, reduces costs, and is safe and easy to use.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.2 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. Omniose announced an expansion of the team in April 2022 with the addition of Timothy Cooke as CEO and Roman Fleck as Chairperson. Both of these highly experienced executives are based in the Boston area. The company also announced the formation of a Scientific Advisory Board with co-founder Mario Feldman and Steven Projan, who brings deep industry experience in infectious disease drug and vaccine development.

OpenCell Technologies™ is a leading innovative company developing a cutting-edge, continuous, scalable, non-viral, cell agnostic soft-poration transfection technology. Our breakthrough platform enables efficient continuous delivery of large cargos into challenging cell types, expanding the frontiers of cell engineering in Biopharma and Cell & Gene Therapy. With precise control at the single-cell level and high throughput, our OpenCell™ technology drives scientific discovery and enhances the effectiveness, affordability, and scalability of current cellular therapies. We empower researchers and clinicians to achieve remarkable advancements in biomedical science and clinical practice.

We're PercayAI, an AI venture providing fundamentally different augmented intelligence software across a variety of healthcare applications, including a variety of healthcare applications, including life sciences, drug discovery, payment integrity, and medical claims. Founded in 2019, PercayAI is made up of an interdisciplinary team with expertise across life sciences, technology and enterprise business who think differently about technology and its impact on our life.

Currently, SafetyFix is the one and only FDA approved removable bone screw on the market with patents in the US, Europe, Canada, China, & Australia. The SafetyFix EasyOut Removable Bone Screw can be used for bone fracture repair and other surgical procedures involving the foot, hand, wrist, ankle, elbow and other small bone corrective procedures. We believe no one should live with metal hardware in their body, which is why we have created the solution.

Formed in 2012 Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of a novel vaccine to prevent bacterial infections, including recurrent urinary tract infections (UTIs) and the treatment of certain cancers and lung infections associated with cystic fibrosis with small molecules.

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. Wugen is based out of St. Louis, Missouri and San Diego, California.